10 billion rubles can be spent on the modernization of Microgen

The state corporation “Rostec” will receive 100% of the shares of FSUE “Microgen” within one and a half years after this enterprise has been reorganized. According to Vedomosti, the corresponding decree was signed by President Vladimir Putin on March 17. After the incorporation, the company must become part of the pharmaceutical holding company National Immunobiological Company (NIK). It should be noted that Microgen itself is now the only Rostec asset in the pharmaceutical industry.

Currently, Microgen is the largest producer of immunobiological preparations in Russia. Revenues for 2014 amounted to 7.6 billion rubles. For the previous year, the amount of revenue is about the same.

NIK plans to focus on five segments of public procurement: vaccines of the national calendar, anti-tuberculosis drugs, blood and human blood plasma, drugs for the treatment of HIV and hepatitis, innovative drugs.
')
In the next five years, about 10 billion rubles will be allocated to modernize the capacities of Microgen. (by estimate). Also, Rostec, according to the contract with the government, has the right to resell the assets of Microgen, but now resale is not being considered, says Nikolai Semenov, CEO of NIK.